Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Centessa Pharmaceuticals PLC has received a consensus rating of "Moderate Buy" from analysts, with one sell, nine buy, and one strong buy recommendations among eleven rating firms.
• The average 1-year price target for the stock is $32.3750, with individual analysts giving price targets ranging from $31.00 to $40.00.
• Recent insider trades included General Counsel Iqbal J. Hussain selling 6,000 shares and insider Mario Alberto Accardi selling 8,172 shares, indicating a decrease in their holdings.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $32.3750.

Several equities analysts recently issued reports on the company. Lifesci Capital upgraded Centessa Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, October 19th. Finally, Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price for the company.

Insider Activity at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total value of $134,460.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at $2,361,700.26. This trade represents a 5.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mario Alberto Accardi sold 8,172 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80. Following the transaction, the insider owned 197,394 shares of the company's stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 146,286 shares of company stock valued at $3,096,605. 7.09% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. HighMark Wealth Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 41.9% in the 1st quarter. HighMark Wealth Management LLC now owns 235,785 shares of the company's stock valued at $3,391,000 after acquiring an additional 69,650 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals during the first quarter worth $147,000. Cerity Partners LLC bought a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $471,000. Wildcat Capital Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth about $4,053,000. Finally, Windmill Hill Asset Management Ltd bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $1,696,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 3.7%

Shares of NASDAQ:CNTA opened at $24.14 on Friday. The company has a 50 day moving average price of $20.83 and a two-hundred day moving average price of $16.14. The company has a market capitalization of $3.23 billion, a PE ratio of -13.49 and a beta of 1.57. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $24.57. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.